TME Pharma: Fast Track designation in glioblastoma
This designation for newly-diagnosed, chemotherapy-resistant glioblastoma with measurable residual tumor post-surgery, follows the FDA's recent approval of the IND application for a Phase 2 study.
Fast Track designation aims to bring new drugs deemed essential to treat serious diseases and unmet medical needs to patients more quickly.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction